SLCO1A2 and glioblastoma: Whilst the majority of OATP immunoreactivity was likely attributed to tumor cell expression in GBM tissue (Figure 2), we did not pursue the analysis of the single-cell expression of OATPs on tumor cells in GBM tissue due to the lack of pan-tumor cell markers in addition to the absence of a meaningful comparison to non-tumor cells.